Literature DB >> 2439904

Interferon-induced revertants of ras-transformed cells: resistance to transformation by specific oncogenes and retransformation by 5-azacytidine.

D Samid, D M Flessate, R M Friedman.   

Abstract

Prolonged alpha/beta interferon (IFN-alpha/beta) treatment of NIH 3T3 cells transformed by a long terminal repeat-activated Ha-ras proto-oncogene resulted in revertants that maintained a nontransformed phenotype long after IFN treatment had been discontinued. Cloned persistent revertants (PRs) produced large amounts of the ras-encoded p21 and were refractile to transformation by EJras DNA and by transforming retroviruses which carried the v-Ha-ras, v-Ki-ras, v-abl, or v-fes oncogene. Transient treatment either in vitro or in vivo with cytidine analogs that alter gene expression by inhibiting DNA methylation resulted in transformation of PR, but not of NIH 3T3, cells. The PR retransformants reverted again with IFN, suggesting that DNA methylation is involved in IFN-induced persistent reversion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2439904      PMCID: PMC365343          DOI: 10.1128/mcb.7.6.2196-2200.1987

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  38 in total

1.  Effects of 5-azacytidine on the progressive nature of cell transformation.

Authors:  W L Hsiao; S Gattoni-Celli; I B Weinstein
Journal:  Mol Cell Biol       Date:  1985-07       Impact factor: 4.272

2.  The action of oncogenes in the cytoplasm and nucleus.

Authors:  R A Weinberg
Journal:  Science       Date:  1985-11-15       Impact factor: 47.728

3.  Suppression of tumorigenicity in hybrids of normal and oncogene-transformed CHEF cells.

Authors:  R W Craig; R Sager
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

4.  Effect of prolonged interferon treatment on mouse embryonic fibroblasts transformed by murine sarcoma virus.

Authors:  C Chany; M Vignal
Journal:  J Gen Virol       Date:  1970-06       Impact factor: 3.891

5.  In vitro establishment is not a sufficient prerequisite for transformation by activated ras oncogenes.

Authors:  B R Franza; K Maruyama; J I Garrels; H E Ruley
Journal:  Cell       Date:  1986-02-14       Impact factor: 41.582

6.  Development of transformed phenotype induced by a human ras oncogene is inhibited by interferon.

Authors:  D Samid; E H Chang; R M Friedman
Journal:  Biochem Biophys Res Commun       Date:  1985-01-16       Impact factor: 3.575

7.  Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells.

Authors:  R L Friedman; S P Manly; M McMahon; I M Kerr; G R Stark
Journal:  Cell       Date:  1984-10       Impact factor: 41.582

8.  Specific growth response of ras-transformed embryo fibroblasts to tumour promoters.

Authors:  G P Dotto; L F Parada; R A Weinberg
Journal:  Nature       Date:  1985 Dec 5-11       Impact factor: 49.962

9.  Effect of 5-azacytidine on DNA methylation and the malignant properties of B16 melanoma cells.

Authors:  D L Trainer; T Kline; F Mallon; R Greig; G Poste
Journal:  Cancer Res       Date:  1985-12       Impact factor: 12.701

10.  Reversibility of the transformed and neoplastic phenotype. IV. Effects of long-term interferon treatment of C3H/10T1/2 cells transformed by methylcholanthrene and SV40 virus.

Authors:  D Brouty-Boyé; J Wybier-Franqui; C Calvo; J Feunteun; I Gresser
Journal:  Int J Cancer       Date:  1984-07-15       Impact factor: 7.396

View more
  12 in total

1.  Resistance to oncogenic transformation in revertant R1 of human ras-transformed NIH 3T3 cells.

Authors:  N Kuzumaki; Y Ogiso; A Oda; H Fujita; H Suzuki; C Sato; L Müllauer
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

2.  Nonterminal differentiation represses the neoplastic phenotype in spontaneously and simian virus 40-transformed cells.

Authors:  R E Scott; D N Estervig; C Y Tzen; P Minoo; P B Maercklein; B J Hoerl
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

3.  Epigenetic inhibition of lysyl oxidase transcription after transformation by ras oncogene.

Authors:  S Contente; K Kenyon; P Sriraman; S Subramanyan; R M Friedman
Journal:  Mol Cell Biochem       Date:  1999-04       Impact factor: 3.396

4.  Developmental characterization and chromosomal mapping of the 5-azacytidine-sensitive fluF locus of Aspergillus nidulans.

Authors:  M Tamame; F Antequera; E Santos
Journal:  Mol Cell Biol       Date:  1988-08       Impact factor: 4.272

5.  A recessive cellular mutation in v-fes-transformed mink cells restores contact inhibition and anchorage-dependent growth.

Authors:  J R Haynes; J R Downing
Journal:  Mol Cell Biol       Date:  1988-06       Impact factor: 4.272

6.  Short-term treatment with gamma interferon induces stable reversion of ras-transformed mouse fibroblasts.

Authors:  B Seliger; K Pfizenmaier; R Schäfer
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

7.  Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate.

Authors:  D Samid; S Shack; C E Myers
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

8.  Posttranscriptional down-regulation of ras oncogene expression by inhibitors of cellular glutathione.

Authors:  A C Miller; J Gafner; E P Clark; D Samid
Journal:  Mol Cell Biol       Date:  1993-07       Impact factor: 4.272

9.  p52(PAI-1) and actin expression in butyrate-induced flat revertants of v-ras-transformed rat kidney cells.

Authors:  P J Higgins; M P Ryan
Journal:  Biochem J       Date:  1991-11-01       Impact factor: 3.857

10.  A novel tetracyclic peptide, trapoxin, induces phenotypic change from transformed to normal in sis-oncogene-transformed NIH3T3 cells.

Authors:  H Yoshida; K Sugita
Journal:  Jpn J Cancer Res       Date:  1992-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.